Our results extend the evidence that, regardless of the insulin delivery method, adjunctive DDP-4 therapy has great potential to help individuals with T1DM achieve meaningful clinical benefits beyond improvement in TIR. This evidence concerns the gene INS and type 1 diabetes mellitus.